Karyopharm Therapeutics Inc
KPTI
NASDAQ
Biotechnology
$2.02
USD
+0.03 (+1.51%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $45.10M
Volume 872.2K
Revenue
$146.62M
TTM
+6.8%
YoY
Gross Margin
96%
TTM
-0.5%
YoY
Net Income
$-224.74M
TTM
-81.9%
YoY
Operating Cash Flow
$-65.35M
TTM
+36.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 37.9 | 44.0 | 34.1 | 35.1 | 33.4 |
YoY Growth | -11.4% | +13.6% | +11.6% | +16.8% | -11.9% |
Cost of Revenue | 1.1 | 2.1 | 1.5 | 1.3 | 1.1 |
Gross Profit | 36.9 | 41.9 | 32.6 | 33.7 | 32.3 |
Selling, General & Administrative | 28.5 | 26.6 | 22.8 | 26.7 | 25.9 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 61.3 | 57.2 | 50.4 | 60.5 | 54.9 |
Operating Income | -24.4 | -15.2 | -17.8 | -26.8 | -22.5 |
EBITDA | -24.3 | -15.1 | -17.8 | -26.7 | -22.5 |
Other Income / Expense | -2.2 | -7.4 | -72.4 | 16.4 | -32.1 |
Total Other Income / Expense | -12.8 | -17.9 | -84.4 | 4.4 | -44.5 |
Income Before Income Taxes | -37.2 | -33.1 | -102.3 | -22.4 | -67.0 |
Income Taxes | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 |
Net Income | -37.3 | -33.1 | -102.2 | -22.4 | -67.0 |
Consolidated Net Income / Loss | -37.3 | -33.1 | -102.2 | -22.4 | -67.0 |
Net Income Attributable to Common Shareholders | -37.3 | -33.1 | -102.2 | -22.4 | -67.0 |
Basic EPS | -$4.32 | -$3.82 | -$5.68 | -$1.02 | -$2.32 |
Diluted EPS | -$4.32 | -$3.82 | -$5.68 | -$1.24 | -$2.32 |
Basic Shares Outstanding | 8.6M | 8.7M | 18.0M | 22.0M | 28.9M |
Diluted Shares Outstanding | 8.6M | 8.7M | 18.0M | 24.7M | 28.9M |